Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

What happened: Recursion Pharmaceuticals reported a third quarter 2026 loss of 22 cents per share, narrower than the Zacks Consensus Estimate of a 24 cent loss, on revenue that beat estimates, driven by a $10 million milestone payment from Sanofi. Key numbers: Loss of 22 cents per share vs. Why it matters: The Sanofi option exercise triggered the milestone payment and keeps Recursion eligible for more than $300 million in additional milestones plus double-digit royalties, while Sanofi funds and leads further development. Recursion carries a Zacks Rank #3 (Hold). Market: -0.2% today ($20.18), +59.4% YTD, 0.1x vol — as of 16:32 UTC Coverage: 6 outlets in 24h

Recursion Pharmaceuticals reported a third quarter 2026 loss of 22 cents per share, narrower than the Zacks Consensus Estimate of a 24 cent loss, on revenue that beat estimates, driven by a $10 million milestone payment from Sanofi.

The Sanofi option exercise triggered the milestone payment and keeps Recursion eligible for more than $300 million in additional milestones plus double-digit royalties, while Sanofi funds and leads further development. Recursion carries a Zacks Rank #3 (Hold). Market: -0.2% today ($20.18), +59.4% YTD, 0.1x vol — as of 16:32 UTC